Nielsen R W
Ear, Nose, and Throat Center of Salt Lake City, Utah.
Am J Med. 1992 Jun 22;92(6A):70S-73S. doi: 10.1016/0002-9343(92)90611-e.
Loracarbef, which is the first agent of the carbacephem class of beta-lactam antibiotics to be developed, provides good activity against a broad spectrum of bacteria. A single-blinded, randomized, parallel clinical trial in 10 centers in the United States compared the efficacy and safety of loracarbef with that of amoxicillin/clavulanate potassium in the treatment of acute bacterial maxillary sinusitis. A 7-10-day regimen of loracarbef (400 mg twice daily) was as effective as amoxicillin/clavulanate (500/125 mg three times a day) and resulted in somewhat fewer side effects. The results of a European trial in Sweden, Finland, and Iceland showed that loracarbef was clinically more effective than doxycycline in the treatment of acute bacterial maxillary sinusitis.
氯碳头孢是首个被研发的碳头孢烯类β-内酰胺抗生素，对多种细菌具有良好的活性。在美国10个中心进行的一项单盲、随机、平行临床试验比较了氯碳头孢与阿莫西林/克拉维酸钾治疗急性细菌性上颌窦炎的疗效和安全性。氯碳头孢7 - 10天疗程（每日两次，每次400毫克）与阿莫西林/克拉维酸（每日三次，每次500/125毫克）疗效相当，且副作用略少。在瑞典、芬兰和冰岛进行的一项欧洲试验结果表明，氯碳头孢在治疗急性细菌性上颌窦炎方面临床疗效优于强力霉素。
